New Publication: Partial loss of desmin expression due to a leaky splice site variant in the human DES gene is associated with neuromuscular transmission defects 

Desmopathies are predominantly autosomal dominant neuromuscular conditions causing adult onset myofibrillar myopathy or cardiomyopathy due to heterozygous DES (DESMIN; OMIM: 125660) mutations. Recessive desminopathies caused by biallelic DES mutations are very rare and often present as more severely progressive myopathies with variable onset. With enriched expression in the postsynaptic membrane of the neuromuscular junction (NMJ), desmin plays a crucial role in structural and functional maintenance of the NMJ. However, except for a single literature report of a family with severe recessive desminopathy due to complete loss of desmin presenting as congenital myasthenic syndrome (CMS), DES mutations have not been reported as a cause of CMS. 

In a new study, “Partial loss of desmin expression due to a leaky splice site variant in the human DES gene is associated with neuromuscular transmission defects” published recently in the journal Neuromuscular Disorders, we identified a recurrent homozygous intronic variant in DES as causative in three previously unsolved limb-girdle CMS (LG-CMS) patients from India. This collaborative study between the Lochmuller Lab and the NIMHANS Neuromuscular team in Bangalore is authored by our postdoctoral researcher and CIHR fellowship recipient Dr. Kiran Polavarapu along with Daniel O’Neil as co-author and Dr. Hanns Lochmuller and Dr. Atchayaram Nalini as senior authors. 

Dr. Kiran Polavarapu used the RD-Connect Genome-Phenome Analysis Platform (GPAP) to re-analyse exomes and genomes of unsolved CMS patients and identified the recurrent intronic mutation (c.1023+5G>A) in three unrelated Indian patients all of whom showed a similar LG-CMS phenotype. Reverse pheno-pathotyping conducted at NIMHANS showed partial loss of desmin and a myofibrillar myopathy pattern associated with desminopathy. Patients also partially benefitted from CMS treatment (salbutamol and pyridostigmine). Research Technician Daniel O’Neil under the guidance of Research Associate Dr. Sally Spendiff conducted RT-PCR and western blot experiments in muscle tissue of one of the patients to reveal the unique splicing defect caused by c.1023+5G>A resulting in only a partially correct splicing site and partial desmin loss correlating with pathology and milder phenotype observed in the patients. 

This study not only established DES as an important CMS-causing gene with recessive inheritance but also identified a likely founder intronic mutation which leads to translational application in diagnosis and early treatment of similar LG-CMS patients especially in the Indian subcontinent. 

Reference: 

Polavarapu, K., O’Neil, D., Thompson, R., Spendiff, S., Nandeesh, B., Vengalil, S., Huddar, A., Baskar, D., Arunachal, G., Kotambail, A., Bhatia, S., Tumulu, S. K., Matalonga, L., Töpf, A., Laurie, S., Zeldin, J., Nashi, S., Unnikrishnan, G., Nalini, A., & Lochmüller, H. (2024). Partial loss of desmin expression due to a leaky splice site variant in the human DES gene is associated with neuromuscular transmission defects. Neuromuscular disorders : NMD, 39, 10–18. Advance online publication. https://doi.org/10.1016/j.nmd.2024.03.011 

New Publication: Partial loss of desmin expression due to a leaky splice site variant in the human DES gene is associated with neuromuscular transmission defects

Read next...

award winners

Celebrating Lab Members’ Recent Research Awards

We are thrilled to celebrate Kelly Ho for receiving first place for her poster presentation at this year’s American Society for Pharmacology and Experimental Therapeutics...
New publication - RTD (2)

Meet The Lochmüller Lab’s Newest Members!

Our research team is growing! We are excited to introduce three new members who have recently joined the Lochmüller lab and several students who will...
McMillan smart study (1)

New Clinical Study Examines Safety and Efficacy of IV Onasemnogene Abeparvovec in Broad SMA Cohort

Pediatric neurologist Dr Hugh McMillan publishes clinical study examining the safety and efficacy of IV onasemnogene abeparvovec in the broadest cohort of SMA patients to...
Text reading: Solve-RD publication: Solve-RD flagship publication: Genomic reanalysis of a pan-European rare-disease resource yields new diagnoses. Photos of Dr Kiran Polavarapu, Dr Rachel Thompson, Dr Hanns Lochmüller.

Solve-RD flagship publication in Nature Medicine: Genomic reanalysis of a pan-European rare-disease resource yields new diagnoses

Patients and families with rare disorders often remain without a genetic diagnosis despite modern advances in diagnostic testing. Due to the rarity and global distribution...
New publication: Identifies Novel ATP2A2 Variant as Genetic Cause of Dominant Rhabdomyolysis . Author's photos on the right, diagram from paper underneath title.

New Lab Publication Identifies Novel ATP2A2 Variant as Genetic Cause of Dominant Rhabdomyolysis

Rhabdomyolysis is an acute failure of cellular homeostasis characterized by acute skeletal muscle damage triggered by trauma, infection, drugs, or strenuous exercise. Recurrent rhabdomyolysis is...
New lab publication on riboflavin transporter deficiency model

New Publication: Development of a riboflavin-responsive model of riboflavin transporter deficiency in zebrafish

Riboflavin transporter deficiency (RTD) is a rare genetic disorder in children, characterised by progressive sensorimotor and cranial neuronopathy caused by mutations in riboflavin transporter protein-encoding...